Yüksel Ürün ASCO Toni Choueiri, MD Nazli Dizman Emre Yekedüz Marc Machaalani Congratulations on the groundbreaking review on IO rechallenge in mRCC! Such insights are crucial for future treatment paradigms.

Nice work!
Top 10 ASCO 2024 Abstracts
Key studies! ASCO Oncology Brothers

With the Premier League title on the line on the final day, all I see are posts about Jurgen Klopp!
RESPECT!
Premier League Liverpool FC #YNWA

A timely and clinically relevant review!
This review provides crucial insights into the treatment of metastatic renal cell carcinoma (mRCC). Congratulations to the entire team on this important contribution! 👏👏👏 ASCO Toni Choueiri, MD Nazli Dizman Emre Yekedüz Marc Machaalani

Join us next Monday for a great YO4YO Clinical Case Discussion with the rising star of Ankara Üniversitesi and the young king of #OncTwitter for 🇹🇷🇹🇷 Erman Akkus

Learning from the great mentors Yüksel Ürün Emre Yekedüz and already taking the stage👏👏

Expect a very strong 🇹🇷🇹🇷 YOs

Congratulations! I am eagerly looking forward to watching it. ESMO - Eur. Oncology

📢🗓️Add to calendar! 🔆
YO4YO Virtual Clinical Case Discussion session ESMO - Eur. Oncology #YOC

✅'Approaching a genomic profiling report for choosing the next line of therapy' 🧬

We will present and discuss the cases on Monday 27, 18.00 CEST
Big thanks to ESMO - Eur. Oncology #YOC for organizing

This reminds me of the NEJM work randomizing early palliative care vs continued systemic therapy, palliative care conferred survival benefit nejm.org/doi/full/10.10…

Inspiring Resilience: Age is Just a Number!
We must look beyond age when evaluating patients. Their vitality and spirit are just as important as any medical assessment!
Enrique Soto Ravindran Kanesvaran OncoAlert American Geriatrics Society SIOG #age Ishwaria Subbiah, MD MS FASCO

Very proud of the great Meeting on #CTC24 hosted in the magical city of Granada Spain 🇪🇸. M JOSE SERRANO (LB&Cancer Interception group) our International Society of Liquid Biopsy Vice president is organizing with Massimo Cristofanilli, MD, FACP our past-president. Great agenda and faculty! Don’t miss it!

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir!

⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler.
⭕️Araştırma, ketojenik

Does oncologic treatment for very advanced disease improve survival?
1⃣The study analyzed 78,446 adult patients with six common metastatic solid tumors. It found no significant survival benefit for patients receiving more systemic therapy for very advanced cancer.
2⃣There was no

Cancer Statistics 2024: Deaths drop, incidences increase, prevention needed!
ACS Journal Cancer OncoAlert American Cancer Society Karen Knudsen, MBA PhD Union for International #CancerControl Oncology Brothers
doi.org/10.1002/cncr.3…

Ketojenik Diyetler Uzun Vadeli Sağlık Sorunlarına Yol Açabilir!

⭕️Science Advances'de yayınlanan yeni araştırmaya göre, ketojenik diyetler (KD) kilo kaybı ve belirli sağlık koşullarının tedavisi için popülerdir, ancak her zaman faydalı olmayabilirler.
⭕️Araştırma, ketojenik

Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results. #LungCancer #NGS #Oncology #PrecisionMedicine
Umberto Malapelle Christian Rolfo

Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC NEJM OncoAlert

Top Advances of the Year: Perioperative Therapy for Lung Cancer

⭕️In 2023, perioperative immune checkpoint inhibitors (ICIs) became a game-changer for early-stage non-small cell lung cancer (NSCLC).
⭕️ Despite these advances, optimizing patient selection and biomarker use

Yine yeniden…